Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth

Aberrant Ras/Raf/MEK/ERK signaling is one of the most prevalent oncogenic alterations and confers survival advantage to tumor cells. Inhibition of this pathway can effectively suppress tumor cell growth. For example, sorafenib, a multi-kinase inhibitor targeting c-Raf and other oncogenic kinases, ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudgeon, Crissy, Peng, Rui, Wang, Peng, Sebastiani, Andrea, Yu, Jian, Zhang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342476/
https://www.ncbi.nlm.nih.gov/pubmed/22286758
http://dx.doi.org/10.1038/onc.2011.644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342476/
https://www.ncbi.nlm.nih.gov/pubmed/22286758
http://dx.doi.org/10.1038/onc.2011.644

Ejemplares similares